Trial
NCT01313273
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Prostate Cancer
Intervention
Lanreotide, non steroidal anti androgens and LHRH-a
Why stopped
Poor enrolment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-22